New research in macaque models has suggested that prior dengue or yellow fever exposure has no significant effects on subsequent Zika infection in vivo, despite demonstrated enhancement in cell culture.
The impact of climate change on infectious diseases in Europe has been assessed in the first large-scale study, with results suggesting the affects could be greater than previously thought.
A chikungunya vaccine, developed by Themis Bioscience GmbH will be assessed for safety and efficacy in Phase II trials in Puerto Rico from August 2017.
Human mobility and globalization have brought new invasive species to other countries. In terms of environment and nature, some of…
We speak to the Aaron Hoyles, the Program Manager of Break Dengue about their disease-surveillance tool, Dengue Track, eHealth and their plans for the future.
Researchers have examined the cerebrospinal fluid in a small cohort of Ebola survivors, reporting that no viral RNA was present and suggesting the virus may be cell-associated within the CNS.
Is a Zika vaccine imminent? Editor, Martha Powell, provides an overview of the current Zika vaccine candidates in human clinical trials and how these vaccines are being assessed.
In this exclusive opinion piece, the authors discuss how ‘OMICS’ can help to unravel molecular dynamics driving the complex biological process involved in disease transmission.
A live-attenuated Ebola vaccine has demonstrated promising results in a Phase I randomized controlled trial assessing safety and immunogenicity, according to a Canadian study.
Researchers investigating Ebola virus have uncovered the function of delta protein, which is released in high levels during infection, and findings suggest it could play a crucial role in disease pathology.
